Sources

7 Total Sources

Daraxonrasib Nearly Doubles Survival in 500-Patient Pancreatic Cancer Trial, Drawing 42-Second ASCO Ovation

Daraxonrasib Drug Trial for Pancreatic Cancer Receives Standing Ovation at ASCO Meeting

Yahoo! Voices5h ago

Standing Ovation Signals Progress Against Pancreatic Cancer at Chicago Meeting

Free Malaysia Today17h ago

Pancreatic cancer pill sparks standing ovation from doctors | FMT

Pancreatic Cancer Treatment Breakthrough with Daraxonrasib | Kiruthiga E posted on the topic | LinkedIn

The Cancer Letter17h ago

Pancreatic cancer finally starts to budge as daraxonrasib doubles overall survival - The Cancer Letter

It's not often that researchers get a standing ovation in the middle of a conference presentation... But that's exactly what happened when researchers showed that the new drug daraxonrasib doubled the survival

Managed Healthcare Executive5h ago

Pashtoon Kasi, M.D., on daraxonrasib's impact on patients: 'You have to see it to believe it' | ASCO 2026 | Managed Healthcare Executive